Oscar Health launches an AI marketplace for health insurance, but the market isn't clearing up doubts about its books

By Zendoric · September 27, 2026. Oscar Health (NYSE: OSCR), a US insurer specializing in individual health policies and classified as a "health tech" company, has unveiled what it calls an "AI Marketplace": a health insurance marketplace mediated by artificial intelligence, according to Simply Wall St. The announcement comes at a delicate moment for the stock: after a very strong run over the past three years, the shares have recently corrected, which reopens the perennial question — is the price still backed by real earnings?

The numbers cited by the source are mixed. The stock trades at a P/E (price-to-earnings, the share price divided by earnings per share) of 16.6 times, below Simply Wall St's peer group, which averages 32.5 times: a meaningful discount to that group, whose composition the source does not detail (it separately mentions, without linking it to the calculation, a selection of 38 AI healthcare stocks as a comparison framework). The same source also puts the traditional insurance sector average at 10.7 times — a figure that in fact sits below Oscar Health's own 16.6x, despite being described as another benchmark against which the stock would be trading "at a discount"—; the comparison, as it appears in the original article, is internally contradictory and should be treated with caution. At its recent Investor Day, management set earnings per share (EPS) targets for 2027 and promised improvements in the medical loss ratio (MLR: the share of premiums the insurer spends on its policyholders' healthcare rather than on operating costs or profit). But according to one of the narratives from the Simply Wall St community — opinions from platform users, not analyst reports from the firm — that ratio already exceeds 91% and continues to rise, alongside what they describe as a pickup in morbidity across the insurance market.

The gap in opinion among those same users is enormous. One narrative puts Oscar Health 95% undervalued; another considers it 18% overvalued. Both look at the same company but reach opposite conclusions depending on which growth and cost-control assumptions they make. It is, in essence, a bet on whether the efficiency promise attributed to AI materializes on the balance sheet before claims costs eat the margin.

Here it is worth being honest about what we know and what we do not. The available material does not explain what exactly this "AI Marketplace" does — whether it automates policy comparison, claims triage, risk underwriting or customer service — and without that technical detail any assessment of its real impact is premature. What is a recognizable pattern is the use of an AI-labeled launch as a narrative catalyst to justify a valuation, while the hard business metrics — a loss ratio the bearish narrative puts above 91% — point in the opposite direction. This is not unique to Oscar Health: it is a familiar script in the digital health of 2026, where the "AI" label sells multiples before it proves cost savings.

Broadly speaking, applying AI to health insurance has genuine potential, aligned with this publication's underlying thesis: systems that better match patients with the right coverage, that detect fraud or that speed up claims handling can genuinely make access to healthcare cheaper, a small but real step toward the abundance we defend over the long term. But that horizon is not proven by a headline or by a P/E lower than a peer group's: it is proven when the loss ratio falls and the policyholder pays less for the same coverage. Until that happens, the prudent course is to treat Oscar Health's "AI Marketplace" as what it is today — a freshly announced corporate promise — and not as a technology already verified in its accounts.